Compare Philip Morris International Inc. (PM) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Philip Morris International Inc. vs BIO-TECHNE Corp — how do they compare? Philip Morris International Inc. trades at $186.66 (market cap $289.45B), while BIO-TECHNE Corp trades at $72.39 (market cap $11.33B). The key difference: Philip Morris International Inc. is far larger — about 25.5× BIO-TECHNE Corp's market cap, and Philip Morris International Inc. pays the higher dividend (3.17%). Which is the better fit depends on your goals.
| PM | TECH | |
|---|---|---|
Market Cap | $289.45B | $11.33B |
Sector | Consumer Staples | Health |
52-Week High | $200.17 | $72.48 |
52-Week Low | $144.33 | $43.31 |
Enterprise Value | $332.56B | $11.35B |
Dividend Yield | 3.17% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Philip Morris International (PM) trades at $185.71, up 1.74% with a bearish technical signal. Recent earnings show beats in Q1 and Q2 2026, but the company cut its 2026 profit forecast due to a $500 million impairment and cost pressures. Fundamentals remain strong with a 25.56% net margin and $11.35B net income in 2025, though high debt and illicit market growth in Europe pose risks. Analyst consensus is bullish with a $211.17 price target.
The stock offers a solid dividend and brand strength via IQOS, but faces headwinds from currency swings, energy costs, and regulatory challenges. Upside depends on execution amid margin pressure, with the current price near the low end of analyst targets suggesting cautious optimism for long-term investors.
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with neutral technical signals and mixed earnings performance. The company reported Q4 2026 revenue of $321.2 million, beating estimates, but net income margins have declined from 25.09% in 2023 to 14.96% in 2026. Key developments include a pending acquisition by Merck KGaA at $73.00 per share and a quarterly dividend of $0.08. Analyst consensus is split with 46% buy and 54% hold ratings.
The stock offers moderate upside to the acquisition price, supported by solid cash flow and institutional interest, but faces risks from margin compression and ongoing shareholder investigations. Valuation multiples like P/E of 62.28 suggest premium pricing, requiring careful assessment of growth sustainability amid competitive and integration challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
